Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?

MLA

Biltaji, Eman, et al. “Can Cost-Effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, vol. 30, no. 6, June 2021, pp. 1106–13. EBSCOhost, https://doi.org/10.1158/1055-9965.EPI-19-1580.

APA

Biltaji, E., Walker, B., Au, T. H., Rivers, Z., Ose, J., Li, C. I., Brixner, D. I., Stenehjem, D. D., & Ulrich, C. M. (2021). Can Cost-effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention? Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 30(6), 1106–1113. https://doi.org/10.1158/1055-9965.EPI-19-1580

Chicago

Biltaji, Eman, Brandon Walker, Trang H Au, Zachary Rivers, Jennifer Ose, Christopher I Li, Diana I Brixner, David D Stenehjem, and Cornelia M Ulrich. 2021. “Can Cost-Effectiveness Analysis Inform Genotype-Guided Aspirin Use for Primary Colorectal Cancer Prevention?” Cancer Epidemiology, Biomarkers & Prevention : A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 30 (6): 1106–13. doi:10.1158/1055-9965.EPI-19-1580.